{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T08:14:58Z","timestamp":1780992898468,"version":"3.54.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2130,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1111\/j.1365-2133.2009.09290.x","type":"journal-article","created":{"date-parts":[[2009,5,5]],"date-time":"2009-05-05T14:25:51Z","timestamp":1241533551000},"page":"1045-1051","source":"Crossref","is-referenced-by-count":180,"title":["Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib"],"prefix":"10.1093","volume":"161","author":[{"given":"W.J.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.E.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.W.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.K.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.H.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.C.","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.K.","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"10.1111\/j.1365-2133.2009.09290.x-BIB1","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the Raf\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"10.1111\/j.1365-2133.2009.09290.x-BIB2","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/jnci\/djj069","article-title":"BAY 43-9006 inhibition of oncogenic RET mutants","volume":"98","author":"Carlomagno","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/j.1365-2133.2009.09290.x-BIB3","doi-asserted-by":"crossref","first-page":"7002","DOI":"10.1200\/jco.2006.24.18_suppl.7002","article-title":"Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. ASCO Annual Meeting, Atlanta, Georgia","volume":"24","author":"Gatzemeier","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1365-2133.2009.09290.x-BIB4","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2006.06.3602","article-title":"Sunitinib: from rational design to clinical efficacy","volume":"25","author":"Chow","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1365-2133.2009.09290.x-BIB5","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1093\/annonc\/mdn389","article-title":"Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib","volume":"19","author":"Lacouture","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1111\/j.1365-2133.2009.09290.x-BIB6","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","article-title":"Cutaneous side-effects of kinase inhibitors and blocking antibodies","volume":"6","author":"Robert","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1111\/j.1365-2133.2009.09290.x-BIB7","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00520-008-0409-1","article-title":"Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib","volume":"16","author":"Rosenbaum","year":"2008","journal-title":"Support Care Cancer"},{"key":"10.1111\/j.1365-2133.2009.09290.x-BIB8","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jaad.2008.06.034","article-title":"Dermatologic symptoms associated with the multikinase inhibitor sorafenib","volume":"60","author":"Robert","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09290.x-BIB9","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1001\/archderm.144.6.779","article-title":"Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib","volume":"144","author":"Hong","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09290.x-BIB10","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jaad.2006.10.032","article-title":"Keratoacanthomas associated with sorafenib therapy","volume":"56","author":"Kong","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09290.x-BIB11","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1001\/archderm.144.6.820","article-title":"Sorafenib-induced eruptive melanocytic lesions","volume":"144","author":"Kong","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09290.x-BIB12","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"10.1111\/j.1365-2133.2009.09290.x-BIB13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/j.1365-2133.2009.09290.x-BIB14","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/02841860701765675","article-title":"Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis","volume":"47","author":"Chu","year":"2008","journal-title":"Acta Oncol"},{"key":"10.1111\/j.1365-2133.2009.09290.x-BIB15","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1001\/archderm.144.7.886","article-title":"Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor","volume":"144","author":"Autier","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09290.x-BIB16","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1634\/theoncologist.2008-0131","article-title":"Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib","volume":"13","author":"Lacouture","year":"2008","journal-title":"Oncologist"},{"key":"10.1111\/j.1365-2133.2009.09290.x-BIB17","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1200\/JCO.2005.06.124","article-title":"Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors","volume":"23","author":"Strumberg","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1365-2133.2009.09290.x-BIB18","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1365-2133.2007.08357.x","article-title":"Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy","volume":"158","author":"Yang","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09290.x-BIB19","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1002\/1097-0142(19950415)75:8<2169::AID-CNCR2820750822>3.0.CO;2-H","article-title":"Hand-foot syndrome associated with liposome-encapsulated doxorubin therapy","volume":"75","author":"Gordon","year":"1995","journal-title":"Cancer"},{"key":"10.1111\/j.1365-2133.2009.09290.x-BIB20","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1200\/JCO.2006.08.9565","article-title":"Hand-foot and stump syndrome to sorafenib","volume":"25","author":"Lai","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1365-2133.2009.09290.x-BIB21","first-page":"753","article-title":"Capecitabine: nursing implications of a new oral chemotherapeutic agent","volume":"26","author":"Mrozek-Orlowski","year":"1999","journal-title":"Oncol Nurs Forum"},{"key":"10.1111\/j.1365-2133.2009.09290.x-BIB22","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/BF00387600","article-title":"Expression of c-kit ligand in human keratinocytes","volume":"286","author":"Morita","year":"1994","journal-title":"Arch Dermatol Res"},{"key":"10.1111\/j.1365-2133.2009.09290.x-BIB23","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1600-0609.2004.00351.x","article-title":"Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib","volume":"74","author":"Breccia","year":"2005","journal-title":"Eur J Haematol"},{"key":"10.1111\/j.1365-2133.2009.09290.x-BIB24","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1200\/jco.2006.24.18_suppl.3004","article-title":"Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab. ASCO Annual Meeting, Atlanta, Georgia","volume":"24","author":"Azad","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1365-2133.2009.09290.x-BIB25","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1096\/fj.03-0271fje","article-title":"Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms","volume":"18","author":"Erber","year":"2004","journal-title":"FASEB J"},{"key":"10.1111\/j.1365-2133.2009.09290.x-BIB26","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.eururo.2007.11.037","article-title":"Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma","volume":"53","author":"Bhojani","year":"2008","journal-title":"Eur Urol"},{"key":"10.1111\/j.1365-2133.2009.09290.x-BIB27","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1096\/fj.00-0368com","article-title":"SCF\/c-kit signaling is required for cyclic regeneration of the hair pigmentation unit","volume":"15","author":"Botchkareva","year":"2001","journal-title":"FASEB J"},{"key":"10.1111\/j.1365-2133.2009.09290.x-BIB28","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1124\/jpet.103.052530","article-title":"Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans","volume":"307","author":"Moss","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/j.1365-2133.2009.09290.x-BIB29","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1056\/NEJM200208083470614","article-title":"Imatinib mesylate and gray hair","volume":"347","author":"Etienne","year":"2002","journal-title":"N Engl J Med"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2133.2009.09290.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2133.2009.09290.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T13:45:53Z","timestamp":1676382353000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/161\/5\/1045\/6642308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,11]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09290.x","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}